Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background and Aim: Linaclotide is a guanylate cyclase‐C agonist approved in multiple countries to treat irritable bowel syndrome with constipation (IBS‐C). China has unmet need for well‐tolerated therapy that is effective in treating both bowel and abdominal symptoms of IBS‐C. This trial evaluated linaclotide's efficacy and safety in IBS‐C patients in China and other regions. Methods: This Phase 3, double‐blind trial randomized IBS‐C patients to once‐daily oral 290‐μg linaclotide or placebo at centers in China, North America, and Oceania. Patients reported bowel and abdominal symptoms daily; adverse events were monitored. Co‐primary and secondary endpoints were tested using a predefined three‐step serial gatekeeping multiple comparisons procedure. Results: The intent‐to‐treat population included 839 patients (mean age = 41 years; 82% female; 81% Asian). The trial met all co‐primary and secondary endpoints. Co‐primary responder criteria were met by 60.0% of linaclotide patients versus 48.8% of placebo patients for abdominal pain/discomfort (≥ 30% decrease for ≥ 6/12 weeks; P < 0.05), and 31.7% of linaclotide versus 15.4% of placebo patients for IBS degree of relief (score ≤ 2 for ≥ 6/12 weeks; P < 0.0001). Secondary 12‐week change‐from‐baseline endpoints (spontaneous bowel movement/complete spontaneous bowel movement frequency, stool consistency, straining, abdominal pain, abdominal discomfort, and abdominal bloating) were significantly improved with linaclotide versus placebo (all P < 0.0001). Diarrhea was the most common adverse event (9.4% linaclotide, 1.2% placebo). Discontinuation rates due to diarrhea were low (0.7% linaclotide, 0.2% placebo). Conclusions: Once‐daily 290‐μg linaclotide improved bowel habits, abdominal symptoms, and global measures in a predominantly Chinese IBS‐C population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Sperber, A. D., Dumitrascu, D., Fukudo, S., Gerson, C., Ghoshal, U. C., Gwee, K. A., Hungin, A. P. S., Kang, J.-Y., Minhu, C., Schmulson, M., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311240 · Cited by 554
Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact
Hungin, A. P. S., Chang, L., Locke, G. R., Dennis, E. H., & Barghout, V. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02463.x · Cited by 494
Chey, W. D., Lembo, A. J., Lavins, B. J., Shiff, S. J., Kurtz, C. B., Currie, M. G., MacDougall, J. E., Jia, X. D., Shao, J. Z., Fitch, D. A., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.254 · Cited by 463
Self-citationCastro, J., Harrington, A. M., Hughes, P. A., Martin, C. M., Ge, P., Shea, C. M., Jin, H., Jacobson, S., Hannig, G., Mann, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.017 · Cited by 295
Self-citationMayer, E. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801447 · Cited by 243
Cited by
Cyclic peptide drugs approved in the last two decades (2001–2021)
Zhang, H., & Chen, S. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00154j · Cited by 319
Black, C. J., Burr, N. E., Quigley, E. M. M., Moayyedi, P., Houghton, L. A., & Ford, A. C. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.021 · Cited by 166
Chang, L., Sultan, S., Lembo, A., Verne, G. N., Smalley, W., & Heidelbaugh, J. J. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.04.016 · Cited by 163
Sharma, A., Rao, S. S. C., Kearns, K., Orleck, K. D., & Waldman, S. A. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16369 · Cited by 84
Metadata
- Authors
- Yang, Y., Fang, J., Guo, X., Dai, N., Shen, X., Yang, Y., Sun, J., Bhandari, B. R., Reasner, D. S., Cronin, J. A., Currie, M. G., Johnston, J. M., Zeng, P., Montreewasuwat, N., Chen, G. Z., & Lim, S.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2018-03-12
- Volume
- 33
- Issue
- 5
- Pages
- 980-989
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W2784164889
- Cited by
- 65
- References
- 8
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. https://app.cochat.ai/papers/10.1111/jgh.14086
- The paper
- Yang, Y., Fang, J., Guo, X., Dai, N., Shen, X., Yang, Y., Sun, J., Bhandari, B. R., Reasner, D. S., Cronin, J. A., Currie, M. G., Johnston, J. M., Zeng, P., Montreewasuwat, N., Chen, G. Z., & Lim, S. (2018). Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.14086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.